三级Gleason 5的转录组特征预测更差的临床病理结局
研究分析159例Gleason分级分组3或4的前列腺癌根治术患者,发现52例(33%)存在三级Gleason 5(TP5),TP5与更高的Decipher评分及中高危风险分类相关,并鉴定出18个差异表达基因,其中CDKN2B、PLK1或CDC20过表达与更差的无进展生存相关。
要点
- 159例GGG 3-4患者中52例(33%)存在TP5,TP5与更高Decipher评分相关(β 0.07,95%CI 0.02-0.13;P=0.04)。
- TP5患者落入Decipher中危或高危类别的可能性更高(OR 3.34,95%CI 1.34-8.35;P=0.01)。
- 至少一个基因(CDKN2B、PLK1或CDC20)过表达组5年PFS率为50%,无过表达组为74%(P<0.001)。
核心结论
- 研究阐明了TP5独特的基因组特征,并证实TP5患者预后更差的既往临床发现。
- 这是首个基于RNA研究TP5分子多样性的研究,也是首个将CDKN2B与前列腺癌更差预后相关联的研究。
研究设计与样本
- 研究纳入159例Gleason分级分组3或4的前列腺癌患者,均接受Decipher诊断检测并获得转录谱及单通道阵列归一化(SCAN)的编码基因表达数据。
- 采用线性和二元逻辑回归分析Decipher与TP5的关系,并对有和无TP5患者进行差异转录组分析。
- 利用癌症基因组图谱(The Cancer Genome Atlas)评估这些基因对无进展生存(PFS)和总生存(OS)的预后作用。
主要发现
- 52/159(33%)患者为GGG 3-4伴TP5疾病。
- TP5与更高的Decipher评分相关(β 0.07,95%CI 0.02-0.13;P=0.04)。
- TP5与落入中危或高危类别的更高可能性相关(OR 3.34,95%CI 1.34-8.35;P=0.01)。
- 微阵列数据分析显示18个基因在TP5患者中差异表达,其中13个基因过表达、5个基因低表达。
- CDKN2B、PLK1或CDC20过表达与更差PFS相关;至少一个基因过表达组5年PFS率为50%,无过表达组为74%(P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the genomic features of tertiary pattern 5 (TP5) on radical prostatectomy specimens in an effort to explain the poor clinical outcomes associated with this disease subtype. PATIENTS AND METHODS: Data from 159 men with Gleason Grade Group (GGG) 3 or 4 were considered. All patients had Decipher diagnostic testing with transcript profiles and single-channel array normalisation (SCAN)-normalised expression of coding genes. The relationship between Decipher and TP5 was investigated by linear and binary logistic regressions. A differential transcriptomic analysis between patients with and without TP5 was performed. The prognostic role of these genes on progression-free survival (PFS) and overall survival (OS) was evaluated using The Cancer Genome Atlas. RESULTS: In all, 52/159 (33%) patients had GGG 3-4 with TP5 disease. TP5 was associated with a higher Decipher score (β 0.07, 95% confidence interval [CI] 0.02-0.13; P = 0.04) and higher likelihood of falling within the intermediate- or high-risk categories (odds ratio 3.34, 95% CI 1.34-8.35; P = 0.01). Analysis of microarray data revealed an 18-gene signature that was differentially expressed in patients with TP5; 13 genes were over- and five under-expressed in the TP5 cohort. The overexpression of cyclin dependent kinase inhibitor 2B (CDKN2B), polo-like kinase 1 (PLK1), or cell division cycle 20 (CDC20) was associated with worse PFS. The group harbouring overexpression of at least one gene had a 5-year PFS rate of 50% vs 74% in the group without overexpression (P < 0.001). CONCLUSIONS: Our studies have elucidated unique genomic features of TP5, whilst confirming previous clinical findings that patients harbouring TP5 tend to have worse prognosis. This is the first RNA-based study to investigate the molecular diversity of TP5 and the first correlating CDKN2B to poorer prognosis in patients with prostate cancer.
引用
- Martini A, Wang J, Brown NM, et al. A transcriptomic signature of tertiary Gleason 5 predicts worse clinicopathological outcome. BJU Int. 2019. PMID: 30825357. doi:10.1111/bju.14740
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。